New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Biodexa Pharmaceuticals PLC

Contributing Author

Recent Articles by Biodexa Pharmaceuticals PLC

Oct-06	Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA - IGC Conference on October 11, 2025 BDRX GlobeNewswire
Sep-12	Interim results for the six months ended June 30, 2025 BDRX GlobeNewswire
Aug-18	Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jul-31	ADR Ratio Change Effective BDRX GlobeNewswire
Jul-15	ADR Ratio Change BDRX GlobeNewswire
Jul-14	Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-27	Results of Annual General Meeting BDRX GlobeNewswire
Jun-25	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-23	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-11	Result of General Meeting BDRX GlobeNewswire
Jun-04	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes BDRX GlobeNewswire
May-30	Shareholder Update BDRX GlobeNewswire
May-22	Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting BDRX GlobeNewswire
May-22	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M BDRX GlobeNewswire
May-12	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP BDRX GlobeNewswire
May-02	Result of General Meeting BDRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.